Life Sciences Archive » October, 2019

Life Sciences - October, 2019

356 articles

• Opioid MDL Attys Poised To Debate Next Bellwether Trials
• Boston Scientific Says Sanctions Stem From 'Fictional Story'
• Ill. Silicone Maker To Probe Possible Contamination After Fire
• Michigan Vape Co. Drops Federal Suit After Ban Paused
• Vanda Pharma Wants Del. Derivative Suit Moved To NY
• IP Law Group Urges High Court To Fix Patent Eligibility
• Fed. Circ. Rules PTAB Judge Appointments Unconstitutional
• 5 Trends Influencing RFPs For Law Firms
• Fed. Circ. Told PTAB Standards 'Eviscerate' Patent Rights
• Biopharma Investor's Letter Dooms Officer Salary Suit
• 2nd Circ. Halves $19.4M Forfeiture In Valeant Kickback Case
• 2 Biotechs Raise Combined $116M After IPOs Price Low
• Pa. Justices To Say If Probationers Can Use Medical Marijuana
• Biotherapeutics Co. Raises $75M In Series B Financing Round
• Arizona's Purdue Suit Violates Ch. 11 Law, High Court Told
• Mass. Judge Refuses To Halt Tweaked Statewide Vape Ban
• Health Care Ad Agency Settles DOJ Fraud Claims For $70M
• Zetia Generic Delay Was A Conspiracy, Court Told
• Sens. Urge Changes At USPTO To Improve Patent Quality
• Fed. Circ. Won't Restore Merck's $2.5B Patent Win Over Gilead
• Tax Court Decision May Open Up New Challenges To 280E
• Dispute Over CBD Sale Doesn't Belong In Colo., Vendor Says
• McKesson Can't Ditch Generic Drug Price-Fixing Fraud Suit
• Vivo Capital Collects $1.43B For Health Care Investment Fund
• 2nd Circ. Mulls Legality Of MD's 'Icky' Drug Stock Trades
• MDLs Are Redefining The US Legal Landscape
• Calif. Labor Law For Cannabis Cos. May Be Unconstitutional 
• L'Oreal Seeks DQ Of Lerner David In Cosmetics IP Row
• What Industry, Investors Think Of The Proposed CFIUS Regs
• Invisalign Maker Exits Shareholder Suit Over Expiring Patents
• Judge Rips Risperdal Trial Team's 'Fabricated' Recusal Bid
• 2nd Circ. Upholds Ex-Katten Atty's Shkreli Fraud Conviction
• Missouri Medical Marijuana Group Asks State For Vaping Regs
• ​​​​​​​Allergan's $750M Deal Among Pharma's Top Antitrust Payouts
• Mitsui Can't Trim Claims It Stole Irrigation System Technology
• New Mass. Vape Ban 'A Mockery' Of Court Orders, Shops Say
• Mallinckrodt Defends Price Hike As Necessary To Save Drug
• Retailers Fight To Keep 3-Way Zetia Conspiracy Claim In MDL
• On-Sale Bar Ruling Invites 'Exploitation,' Justices Told
• Fed. Circ. Tells PTAB To Review All Claims Of Drug Test Patent
• Why I Became A Lawyer: Being There For Families In Trouble
• Grunenthal Earns PTAB Win In Challenge To Pain Treatment IP
• Protecting Against Corruption In State Cannabis Licensing
• Labaton, Levi & Korsinsky Seek $4.7M Fees For Prothena Suit
• Hemp Regulation Turns Corner With New USDA Rule
• Drugmakers Ink $242M Settlement In Ill. Medicaid Fraud Case
• J&J Discloses Grand Jury Subpoena For Opioid Distributions
• Utah Judge Puts Emergency Flavored Vape Rule On Hold
• Calif. Cannabis Patient Takes Edible Eviction Case To 9th Circ.
• Foley Hoag Partner Takes Over As AIPLA President
• FTC Rips Gilead's 'Erroneous' Argument In HIV Drug Rumble
• Insys Doc's Sentence Called A Warning To Medical Community
• 3rd Circ. Revives Merck's Arbitration Bid In Vaccine Suit
• Takeda Hid 'Dangerously Defective' Gout Drug's Risks
• Philly Jury Hits Vein Filter Co. With $34M Defect Award
• Best Practices For US-Canada Virtual Mass Tort Teams
• Chinese Distributor Can't Pause US Co.'s Trade Secrets Suit
• Confronting Plaintiffs Attorney Advertising Abuses
• Allergan Paying $750M To End Namenda Antitrust Fight
• PixarBio CEO Found Guilty In Stock Fraud Case
• 5 Firms Guide Fintech, Biotech IPOs Totaling $295.8M
• Romanucci Atty Will Lead Sterigenics Emissions Suits In Ill.
• CBD Rules In Limbo As FDA Grapples With New Cannabis Era
• Woman Wants New Trial In Sanofi Chemo Drug Bellwether
• Silicone Maker Owes $1.6M After Deadly Blast, OSHA Says
• Vein Filter Patient Could Die, Philly Jury Told At Trial's End
• In Lung Injuries Probe, Officials Are Looking Beyond THC
• Glancy Prongay & Murray Will Lead Omnicell Stock Drop Suit
• PE Firm's Bid To Force Sale of Colo. Cannabis Retailer Tossed
• Pharmacy Claims Online Rx Co. Strangled Market
• Novartis Sues Indian Generic Cos. Over Heart Failure Drug IP
• Reckitt Spared Fees In 'Close Call' After Losing Mucinex Suit
• Ethicon Can't Escape Damages Claims In Pelvic Mesh Suit
• $16.7M AbbVie Inversion Settlement Gets Final Approval
• Lilly Says It Didn't Give Up Alternatives By Narrowing Patent
• Fed. Circ. Rehearing Requests Patent Attys Should Watch
• Counseling Cannabis Cos. Requires A Holistic Approach
• States Are Wrong To Block Local Gov'ts From Opioid Suits
• Patient Assistance Groups Settle Kickback Claims For $6M  
• Cooley-Led Fertility Benefits Co.'s $130M IPO Misses Target
• Goodwin-Led Cabaletta Prices Below Range With $75M IPO
• Recent Antitrust Lessons For The Life Sciences Industry
• CVS Yanks J&J Baby Powder From Stores After Recall
• RI Flavored Vape Ban Latest To Face Court Challenge
• Associates Found Guilty In Doc's Major Oxy-Pushing Scheme
• Canadian Boutique Woods Adds Squire Patton Int'l Arb. Atty
• Pfizer's PTAB Appeal 'At War With Itself,' Fed. Circ. Told
• FDA Yanks Homeopathy Compliance Policy As Inadequate
• Chancery Orders Keryx To Turn Over Akebia Merger Records
• 4th Circ. Wrong To Dismiss Pelvic Mesh Appeal, Firm Says
• DOJ Strikes $6.4M Deal With Engineering Co. Over Billing Spat
• Deals Rumor Mill: Paysafe, Reynolds, Banijay Group
• Vape Co. Must Pull Illegal Ads For 100 Products, FDA Warns
• GSK Loses Bid To End 53 Zofran Birth Defects Cases
• UK Outlines Issues With Illumina's $1B DNA Sequencing Buy
• Examine Diversity Jurisdiction By Drilling Into Citizenship
• Device Maker, Execs To Pay $6M To End Feds' FCA Claims
• Loestrin Buyers' $1M Lupin Deal Gets Initial Approval
• New Technology Could Shape How Patents Are Valued
• Hong Kong Childhood Can't Diminish J&J Talc Risk, Jury Told
• 4 Takeaways From The USPTO's Patent Eligibility Update
• No Class Cert. In Boston Scientific Robocall Suit, Judge Says
• Okla. Judge Temporarily Blocks Reversible Abortion Info Law
• Birth Defect Report Trimmed By Judge In Zofran MDL
• IRS Bar On Pot Biz Deductions Constitutional, Tax Court Says
• Fla. Pharma Lab Says Patent Licensee Hid Payments
• Surgeon General Warns Senate About Perils Of Legalizing Pot
• American With Greek Ties Denied Bail In Insider Trading Case
• Ky. AG Announces $40M In Settlements With Bayer, Reckitt
• Where Law Firm Partners Go When Changing Jobs
• FDA Struggles To Foster An Affordable Biosimilar Insulin
• Nerve Repair Co. Says Derivative Suit Lacks Demand Futility
• FDA To Require Warning Labels On Breast Implants
• Asbestos Slipped Into J&J's Talc Supply, LA Jury Hears
• Feds Slam Pharma CEO's Bid To Nix Opioid Trafficking Charge
• Takeda Unit's Workers Get OK On $4.8M Deal In Wage Suit
• PTAB Allows Amendments To Jevtana Patent On Remand
• Momenta, Sandoz Can't Pause Blood-Clot Drug Antitrust Suit
• 10x Genomics To Pay Becton $25M In Cell Analysis IP Deal
• 'Mootness Fees' Are Beyond Court's Purview, 7th Circ. Hears
• California's Pot Regulation Maze Keeps Businesses On Edge
• Goldman Banker Denies Insider Trading As Gov't Suspects 6
• 3 Ways To Leverage Vulnerability For Lawyer Well-Being
• Hyland's Must Face Revived Suit Over Infant's Death
• Clinical Trials And Specific Jurisdiction After Bristol-Myers
• FDA, FTC Issue Warning On Claims CBD Can Treat Diseases
• The FDA Regulatory Landscape For Tobacco And Cannabis
• Cooley-Led Rapt Therapeutics Renews IPO Plans
• RI Governor Sues Lawmakers Over Control Of Cannabis Regs
• Pfizer, Sanofi Sued Over Possible Zantac-Cancer Link
• Pot Co. Harborside Gets $11M Bill After Tax Code Fight
• 3rd Circ. Declines To Reconsider J&J Remicade Antitrust Case
• Pharma Co. Blames BakerHostetler For Investor Row
• $48B Opioid Deal Outcry May Presage Plaintiff Infighting
• Lead Counsel Field In Curaleaf Stock Suit Narrowed To 2
• Oregon Pot Shop Will Give Up License Over Same-Day Sales
• Fed. Circ. Backs PTAB Ruling On Corning Cell Culture IP Row
• State AGs Reach $48B Proposed Deal To End Opioid Cases
• Keeping Sponsored Content On The FTC's Good Side
• Workers Say J&J Could Have 'Told Truth' On Talcum Powder
• Medical Pot Co. Worker Sues For Retaliation, Discrimination
• 2nd Circ. Revives Part Of EmblemHealth Execs' Benefits Suit
• Novartis Hit With Retaliation Suit Over Kickback Scheme
• Cooley, Baker McKenzie Steer Vaccine Deal Worth Up To $1.06B
• Kirkland Leads Danaher In $750M Divestiture For GE Deal
• High Court Passes On Lilly's $20M Cialis Patent Loss
• Opioid Trial Halted By Drug Cos.' 11th Hour $260M Deal
• Humana Slaps Generic-Drug Makers With New Price-Fix Suit
• McKesson Faces Uphill Fight To Toss Investor Price-Fix Suit
• Fight Over Utah's Medical Pot Effort Bumped To State Court
• DC Circ. Tosses Medical Pot Researcher's Fight With DEA
• La. Insurer Sues Pharma Cos. Over Opioid Crisis
• Dova Pharma Hit With Investor Suit Over $915M Sobi Tie-Up
• PTAB Gives Sanofi First-Ever Early Feedback On Amendments
• AstraZeneca's IP Suit Sent To W.Va. On TC Heartland Grounds
• Ill. City Ran To Court In Discovery Row, Express Scripts Says
• New Data Shows BigLaw's True Profitability
• PTAB Told To Weigh Invalid Claim Language In Ethicon Patent
• Health Hires: White & Case, Epstein Becker
• How 280E Became The Pot Industry's Boogeyman
• NECC Pharmacists Lose Bid For New Trial In Meningitis Case
• Zoning Compliance Tips For NJ Medical Marijuana Facilities
• J&J Pans Judge's 'Partisan Glee' After $8B Risperdal Verdict
• J&J Recalls Asbestos-Tainted Baby Powder Flagged By FDA
• Ex-Biotech Exec Agrees To Penalty For Deceiving Auditors
• What To Watch As Opioid MDL Nears Moment Of Truth
• Judge Questions Eagle's Orphan Drug Market Exclusivity
• Vein Filter Co. Boss Dinged For Talking To Plaintiff From Stand
• New USPTO Patent Eligibility Guidance Aims For More Clarity
• Oregon's Flavored Vape Ban Put On Hold Amid Legal Fights
• Ex-Okla. Gov't Atty Admits Fake Death Threats Over Pot Laws
• Under Siege, Juul Pulls Most Flavors From US Market
• Actavis Asks Full Fed. Circ. To Nix 'Amorphous' Panel Ruling
• Cooley, Linklaters Steer $69M Biotech IPO, Private Placement
• Insys Exec Trial Fair Despite Alleged Weil Conflict, Judge Says
• Boston Scientific Sanctioned For 'Shenanigans' In FCA Suit
• Mylan Case Shows SEC Stance On Disclosing Investigations
• AmerisourceBergen Brass Sued In Del. Over Drug Scheme
• SmileDirect Accuses Calif. Dental Board Of Harassment
• HHS Anti-Kickback Proposal Features 3 Key Safe Harbors
• J&J To Pay States $117M To Quell Pelvic Mesh Suits
• 8 Best Practices For Cannabis Transaction Due Diligence
• Pa. Justices Ask If Judge Delved Too Deep Into Science
• Vape Flavor Ban May Create Black Market, Lawmakers Told
• Toss 3-Way Zetia Conspiracy Claim, Judge Says
• Mass. Vaping Illnesses Mount As Legal Fight Over Ban Swirls
• Drug Cos. Float Deals Worth $50B To End Opioid Cases
• Shkreli Asks Justices To School 2nd Circ. On Securities Fraud
• Allergan Clashes With Buyers Over Cert. Bid In Antitrust MDL
• PTAB Won't Rehear Challenge To Prostate Cancer Drug Patent
• Insys Judge Unsure If Execs' Bribes Equal Drug Dealing
• Sandoz Revealed Trade Secrets In Antitrust Suit, Court Told
• Fla. High Court To Review Ruling Against Medical Pot Regs
• Suzanne Somers Says QVC Sabotaged Her Supplement Biz
• Goodwin-Led Cabaletta Bio Launches $87M IPO
• Alexion Set To Buy Clinical-Stage Pharma Biz In $930M Deal
• PTAB Sheds Light On Its Discretion To Hear IPRs
• Calif. Pot Cos. Must Sign 'Labor Peace' Deals After 20th Hire
• True Health Set To Begin Soliciting Votes On Ch. 11 Plan
• Missouri Appeals Court Erases $110M Talc Loss For J&J
• AmerisourceBergen Fights To Shield Opioid Docs At Chancery
• Michigan Vape Ban Halted After Claims Of Business Harm
• Fenwick Hires 2 Corporate Tech Pros On The West Coast
• High Court Declines To Hear 2 Patent Cases
• AbbVie Says Humira's Many Patents Is No Antitrust Violation
• 'Novel' Disclosure Issue Not Ready For Del. Supreme Court
• How AI Is Shaping FDA Medical Device Regulation
• Benefits, Biopharma And Boat Cos. Prep IPOs Totaling $360M
• Ex-Katten Atty's Jury Gripe Falls Flat With 2nd Circ. Judge
• IPRs Will Bleed Budgets And Innovation, States Warn Justices
• Grading The Presidential Candidates On Cannabis Policy
• High Court Won't Hear $2.7M Fees Appeal In BioScrip Deal
• Courts Keep Rejecting Litigation Funding Discovery Campaign
• Teva, Mylan, Other Generic Makers Hit With Price-Fixing Suit
• Fed. Circ. Backs PTAB's Gutting Of Duke Muscle Treatment IP
• Purdue Opioid Suits Get One-Month Pause, For Now
• Akin Gump's Local Focus Helped Land Bull Semen IP Win
• Generics, Others Back Impax Against FTC In 5th Circ.
• Sorin Settlement Offers Heart Patients Free Monitoring
• J&J Wins Second Asbestos-In-Talc Trial In A Week
• Mass. Gov. Fights To Keep Vape Ban Fight In Fed. Court
• Justices Seem Skeptical Of USPTO's Attorney Fee Arguments
• Restasis Payors Defend Class Cert. Bid In Allergan Suit
• How Emotionally Intelligent AI Could Assist With E-Discovery
• 8th Circ. Won't Rehear Monsanto Label Settlement Objection
• Chicago's Ex-Chief Judge Turns To 'Unfinished Business'
• FDA Focus: What BakerHostetler's Practice Chair Is Watching
• Glaukos Beats Last Of Rival's PTAB Challenges To Stent IP
• Job Wrongly Rescinded Over Medical Marijuana, Pa. Man Says
• Biotech, Bank Raise Combined $276M In Low-Priced IPOs
• 19 Abilify Claims Tossed As Lacking Proof In MDL Settlement
• Fed. Circ. Bars Generic Of Horizon Arthritis Drug Until 2027
• FCA Decision Tracker: Continued Interpretations Of Escobar
• Dental Startup Settles With Last Distributor In Boycott Suit
• Court Told Settlement Is The Best Result For Purdue Ch. 11
• Target Can't Pass Buck On Antibiotic Labeling Suit Costs
• Purdue Docs Show DOJ Deal Is Key To Ch. 11 Settlement
• J&J Nears OK For $6.3M Deal In Infant Tylenol False Ad Suit
• UBiome's Ch. 7 Case Conversion Approved In Del.
• Mich. Pot Testing Lab Fined $100K Over Flawed Methods
• 4 Firms Steer BioNTech's Downsized $150M IPO
• J&J Beats Class Action Over Opioid Health Insurance Costs
• The Number Of Cannabis-Centric Patents Is Getting High 
• Ginkgo Bioworks Unveils $350M Biotech Spinoff Fund
• Preventable Risks Your Law Firm May Be Overlooking
• Ohio Trial In Opioid MDL Will Go Forward, 6th Circ. Says
• Covington & Burling, Latham Lead UCB's $2B Ra Pharma Buy
• Genetic Testing Co., 3 Others To Pay $42.6M Over FCA Claims
• Manatt Nabs Former McDermott Litigation Pro In LA
• Conn. Fits Teva Stock-Drop Suit Better Than Pa., Judge Says
• Chinese Distributor Can't Shake Trade Secrets Suit
• J&J Cleared By Calif. Jury In Talc Cancer Retrial
• $8B Philly Risperdal Verdict Ripe For Reduction, Experts Say
• Salix Pharma Beats Ex-Worker's FCA Retaliation Suit
• Fresenius To Pay $5M To Resolve Mass. Medicare Fraud
• Doc Who Led Major Oxy-Pushing Scheme Working With Feds
• 6 Ethics Tips For Attorneys Making Lateral Transfers
• Dickinson Wright Adds Cannabis Pro In Ohio
• FTC Warning On Plaintiffs Bar Advertising Is Timely
• Failure To Launch: The Patent Thicket Delay Of US Biosimilars
• Arizona Backs Out Of Purdue's Opioid Settlement
• PixarBio CEO's Greed Drove Stock Fraud, Boston Jury Hears
• Ex-Biomet Employee Can't Sue Over FCPA Firing: 7th Circ.
• Questions Swirl Around Opioid MDL Bellwether Trial
• Purdue's Sackler Family Loses Bid To Toss Mass. Opioid Suit
• Purdue Agrees To Put Off Consideration Of Ch. 11 Bonuses
• Levi & Korsinsky Picked To Lead Corcept Stock Drop Suit
• Ga. Jury Deadlocks In Latest J&J Talc Cancer Trial
• Sun Pharma Biosimilar Infringes Galderma Oracea Patents
• Takeda Avoids Most Claims In Actos Buyers' Antitrust Suit
• Full Fed. Circ. Asked To Undo Ruling That 'Disrespects' States
• Investor Suing Insys 'Not Listening' To Court, Judge Scolds
• Vein Filter Co. Ignored Potential Defects, Philly Jury Told
• NY's Most Prolific Oxy Doc Set To Plead Guilty, Feds Say
• J&J Slammed With $8B Verdict In Philly Risperdal Case
• Attys Denied Fee Set-Aside In Generics Antitrust Case
• Insys Seeks Extension Of Ch. 11 Plan Exclusivity Period
• Cannabis Cos. MedMen And PharmaCann Cancel $682M Deal
• Calif. Becomes 1st State To Target 'Pay-For-Delay' Drug Deals
• Merck Fires Back At Pfizer's Bid To Nix Trade Secret Suit
• J&J Talc Trial Closes With Each Side Blasting Other's Experts
• Hemp Co. Says Retailer Backed Out On CVS Distribution Deal
• USPTO To Revise Patent Term Rules After Fed. Circ. Ruling
• Philly Trial May Signal Future Vein Filter Claim Success
• Medical Co. Beats Claims Kid's Health Costs Got Dad Fired
• Fed. Circ. Reverses Brainlab MRI Patent Win
• Pomerantz, Wolf Haldenstein Vie To Lead Curaleaf Stock Suit
• Chinese Home Rental Biz Q&K Taps Cleary Gottlieb For IPO
• Justices Won't Hear Pharma Case Over FCA's Public Info Bar
• Monsanto's Final Roundup Trial Of 2019 Called Off Indefinitely
• J&J Can't Split Up Punitive Damages Trial In NJ Talc Case
• Employers Look To NJ High Court For Clarity On Medical Pot
• Nutrition Food Biz Joins Pipeline With Potential $525M IPO
• Bid To Boot Opioid Judge Raises Questions On Judicial Roles
• High Court Skips Ex-Pfizer Exec's ERISA Venue Case
• FTC Distorted Actavis Ruling In Generics Dispute, Impax Says
• Retailers Win Fight Over How To Carve Loestrin Antitrust Trial
• 25 AGs Say Purdue, Sackler Suits Should Proceed In Ch. 11
• Cooley Says Theranos Founder Holmes Not Paying Legal Bills
• FDA Chief Warns Against Use Of THC Vapes Amid Crisis
• Lab Investor Hits CBD Co. With Securities Fraud Suit
• Fed. Circ. Reverses Apotex's PTAB Win On OSI Cancer Drug
• Fed. Circ. Won't Revive 23AndMe Patent Axed Under Mayo
• AdvoCare Deal Puts FTC's 13(b) Authority In Spotlight
• 3 Things To Watch As USPTO's Fee Rule Hits The High Court
• Feds, States Won't Join Allergan Glaucoma Drug FCA Suit
• 7 Firms To Guide 3 IPOs Totaling $550M, Led By Biotech Cos.
• Unilever Deodorant Causes Stains It Claims To Stop, Suit Says
• USPTO's Battle For Attorney Fees, Explained
• NY, Calif., 24 Other States Fight Purdue's $38M Bonus Plan
• Ex-Rep. Chris Collins' Son Cops To Insider Trading Scheme
• NY Appeals Court Temporarily Blocks Flavored Vape Ban
• Risperdal Marketing Blocks Weren't For Kids, Pa. Jury Told
• CDC, FDA Ramp Up Vape Alarms As Lung Injury Cases Top 1K
• Clark Hill Says It Can't Be Sued Over Client's Settlement
• Icosavax Closes $51M Series A, Officially Launches
• Momenta, Sandoz Try To Pause Blood-Clot Drug Antitrust Suit
• DuPont Lined Its Pockets With Forfeited Benefits, Retiree Says
• Wilson Sonsini Steers Tenaya Therapeutics To $92M Series B
• FTC Seeks E-Cigarette Cos.' Data On Advertising, Sales
• 4 Plead Not Guilty To $99M Health Care Fraud In NJ
• Biotech Cancels IPO While 3 Others Launch In Choppy Market
• Vaping Crisis Raises New Liability And Insurance Issues
• Consider The Power Of Tactical Empathy
• Trevena Says Investors' Key Doc Contradicts Fraud Claims
• Ex-Theranos CEO Says Feds' Discovery Delay Is 'Deja Vu'
• Justices Urged To Heed 'Clarion Call' And Fix Patent Eligibility
• Medtronic Tells Justices $23M IP Verdict Flouts On-Sale Bar
• 4 Key Moments From J&J's Mesh Marketing Battle With Calif.
• AdvoCare Pays $150M To Settle FTC Pyramid Scheme Claims
• FDA Warns Of Security Flaws Lurking Within Medical Devices
• Gov't Says No Need To Revisit FCA Dismissal Authority
• 3rd Circ. Doubts Merck's Arbitration Bid In Vaccine Suit
• Opioid Distributor CEO Seeks To Toss Drug Trafficking Charge
• JPML Sends Juul Marketing Suits To Calif.
• Par Settlement Gets OK In Zetia Generic Delay Case
• FDA's New Medical Device Rules Speed Up Review Process
• The Problem — And Opportunity — Of Implicit Bias In The Bar
• White & Case, O'Melveny Lead $520M Progenics Buy
• Wisconsin Trailing In Midwest's Race To Legalize Cannabis
• UBiome Seeks Liquidation As Creditors Balk On DIP Loan
• J&J Inks $20.4M Deal Just Ahead Of Opioid Bellwether
• Undeveloped Patent Cases Leave Fed. Circ. In Dark: Judge
• Opioid MDL Judge Rips Ohio AG's Late Bellwether Attack
• Zydus Pins Its Patent Loss On Co-Defendant At Fed. Circ.
• Chancery OKs Anixa Reform Deal To End Repriced-Stock Suit
• Walgreens Ditches FCA Suit Over Prescription Autorefills
• Cannabis Industry Lobby Says FDA Should Regulate Legal Pot
• Sandoz Hit With Patent Suit Over Bausch's IBS Drug Xifaxan
• 2 Firms Eclipse Peers In IPO Work During Choppy September
• Judging A Book: Thapar Reviews Gorsuch's 'A Republic'
• Defendants' Chances On Daubert May Vary By Circuit
• DEA Slow To Act In Opioid Crisis, Inspector General Says
• Ex-NY Rep. Collins Cops To Insider Trading, Lying To FBI
• 2 Trends In DOJ Health Care Enforcement
• Drug Cos. Push 6th Circ. To Disqualify Opioid MDL Judge